• 975 Citations
  • 17 Scopus h-Index
20052019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Sikander Ailawadhi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 19 Similar Profiles
Multiple Myeloma Medicine & Life Sciences
Waldenstrom Macroglobulinemia Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Dexamethasone Medicine & Life Sciences
Survival Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Epidemiology Medicine & Life Sciences
B-Cell Chronic Lymphocytic Leukemia Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2005 2019

Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma

Ailawadhi, S., DerSarkissian, M., Duh, M. S., Lafeuille, M. H., Posner, G., Ralston, S., Zagadailov, E., Ba-Mancini, A. & Rifkin, R., Jan 1 2019, In : Clinical therapeutics.

Research output: Contribution to journalArticle

Multiple Myeloma
Costs and Cost Analysis
Therapeutics
Dexamethasone
Subcutaneous Infusions
4 Citations (Scopus)

Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma

Jagannath, S., Heffner, L. T., Ailawadhi, S., Munshi, N. C., Zimmerman, T. M., Rosenblatt, J., Lonial, S., Chanan Khan, A. A., Ruehle, M., Rharbaoui, F., Haeder, T., Wartenberg-Demand, A. & Anderson, K. C., Jan 1 2019, In : Clinical Lymphoma, Myeloma and Leukemia.

Research output: Contribution to journalArticle

Multiple Myeloma
Appointments and Schedules
Neoplasms

Influence of Sociodemographic Factors on Treatment Decisions in Non–Small-Cell Lung Cancer

Duma, N., Idossa, D. W., Durani, U., Frank, R. D., Paludo, J., Westin, G., Lou, Y., Mansfield, A. S., Adjei, A. A., Go, R. S. & Ailawadhi, S., Jan 1 2019, (Accepted/In press) In : Clinical Lung Cancer.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Treatment Refusal
Drug Therapy
Therapeutics
Radiotherapy

Monoclonal antibody utilization characteristics in patients with multiple myeloma

Ailawadhi, S., Sher, T., Azzouqa, A. G., Meghji, Z., Jain, T., Jani, P., Ahmed, S., Diehl, N., Roy, V., Shah, V., Hodge, D., Ailawadhi, M., Alegria, V. R., Paulus, A., Chanan Khan, A. A. & Fonseca, R., Sep 1 2019, In : Anti-cancer drugs. 30, 8, p. 859-865 7 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Monoclonal Antibodies
Premedication
Clinical Trials
Drug Utilization

Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies

Siddiqi, T., Frankel, P., Beumer, J. H., Kiesel, B. F., Christner, S., Ruel, C., Song, J. Y., Chen, R., Kelly, K. R., Ailawadhi, S., Kaesberg, P., Popplewell, L., Puverel, S., Piekarz, R., Forman, S. J. & Newman, E. M., Jan 1 2019, (Accepted/In press) In : Leukemia and Lymphoma.

Research output: Contribution to journalArticle

Aurora Kinase A
Histone Deacetylase Inhibitors
Neoplasms
Appointments and Schedules
vorinostat